Literature DB >> 2328994

Confirmation of linkage in von Hippel-Lindau disease.

J M Vance1, K W Small, M A Jones, J M Stajich, L H Yamaoka, A D Roses, W Y Hung, M A Pericak-Vance.   

Abstract

Von Hippel-Lindau (VHL) disease was initially reported to be linked to the RAF1 oncogene (3p25). We have ascertained and sampled two large multigenerational VHL families for linkage studies, in order to confirm the localization of the VHL gene as a prelude to fine mapping studies. The probes used in the analysis were p627 (RAF1) and pHeA12 (thyroid hormone receptor B) (3p24.1-3p22). VHL was analyzed as an autosomal dominant trait with age-dependent penetrance. The maximum lod score combining both families was z(theta) = 2.16 at theta = 0.0 for RAF1 and z(theta) = 2.20 at theta = 0.05 for thyroid hormone receptor B. Multipoint analysis using the RAF1 and thyroid hormone receptor B loci resulted in a peak lod score of 3.1 confirming linkage of VHL to this region of chromosome 3. However, the position of VHL relative to the two loci could not be established with certainty.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328994     DOI: 10.1016/0888-7543(90)90488-g

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  5 in total

1.  Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus.

Authors:  G M Glenn; L N Daniel; P Choyke; W M Linehan; E Oldfield; M B Gorin; S Hosoe; F Latif; G Weiss; M Walther
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

2.  Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease.

Authors:  B R Seizinger; D I Smith; M R Filling-Katz; H Neumann; J S Green; P L Choyke; K M Anderson; R N Freiman; S M Klauck; J Whaley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

3.  Genetic mapping of dinucleotide repeat polymorphisms and von Hippel-Lindau disease on chromosome 3p25-26.

Authors:  M A Pericak-Vance; K J Nunes; E Whisenant; D B Loeb; K W Small; J M Stajich; J B Rimmler; L H Yamaoka; D I Smith; H A Drabkin
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

4.  Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.

Authors:  H J Decker; C Neuhaus; A Jauch; M Speicher; T Ried; M Bujard; H Brauch; S Störkel; M Stöckle; B Seliger; C Huber
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

5.  von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis.

Authors:  M Yao; F Latif; M L Orcutt; I Kuzmin; T Stackhouse; F W Zhou; K Tory; F M Duh; F Richards; E Maher
Journal:  Hum Genet       Date:  1993-12       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.